NCT01417546View on ClinicalTrials.gov

NHS-IL12 for Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 12, 2011

Primary Completion Date

June 2, 2021

Study Completion Date

October 14, 2021

Conditions
Epithelial Neoplasms, MalignantEpithelial Tumors, MalignantMalignant Mesenchymal Tumor
Interventions
DRUG

NHS-IL-12

NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01417546 - NHS-IL12 for Solid Tumors | Biotech Hunter | Biotech Hunter